NCT04713046
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
At risk: Primary completion moved 2 months later.
See at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary and study completion pushed from Oct 1, 2026 to Dec 1, 2026
- Secondary endpoints: details revised at 3 of 5 entries
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Site details revised
- Minor Site contact updatedv14
- Notable Primary and study completion dates: Oct 1, 2025 to Oct 1, 2026v13
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Primary and study completion dates: Aug 1, 2025 to Oct 1, 2025
- Start date changed from estimate of Oct 1, 2023 to Oct 18, 2023
Show 9 earlier versionsHide 9 earlier versions
- Notable Start date: Aug 1, 2023 to Oct 1, 2023v10
- Notable Start date: May 15, 2023 to Aug 1, 2023
- Primary and study completion dates: May 31, 2025 to Aug 1, 2025
- Notable Start date: Mar 15, 2023 to May 15, 2023
- Primary and study completion dates: Mar 31, 2025 to May 31, 2025
- Notable Primary and study completion dates: Mar 31, 2024 to Mar 31, 2025
- Start date: Nov 15, 2022 to Mar 15, 2023
- Notable Start date: Sep 15, 2022 to Nov 15, 2022v6
- Notable Start date: Jun 15, 2022 to Sep 15, 2022
- Primary completion date: Dec 31, 2023 to Mar 31, 2024
- Study completion date: Dec 31, 2024 to Mar 31, 2024
- Notable Primary completion date: Dec 31, 2022 to Dec 31, 2023
- Study completion date: Dec 31, 2022 to Dec 31, 2024
- Notable Start date: Jan 15, 2022 to Jun 15, 2022v3
- Notable Start date: Jul 1, 2021 to Jan 15, 2022v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
Biologicals: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Sites
1 site in 1 country
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United States